U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07482059) titled 'A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma' on Feb. 27.
Brief Summary: This clinical trial was designed to evaluate the safety and efficacy of Y90-SIRT combined with nivolumab, ipilimumab, and lenvatinib in patients with unresectable HCC. In addition to assessing short-term efficacy endpoints, such as ORR and PFS, this trial places particular emphasis on the OS benefit for patients. This study is therefore both novel and innovative.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Unresectable Hepatocellular Carcinoma
Intervention:
DRUG: ttrium-90 microspheres ...